Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients

Next Previous
Trial Profile

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Prednisone
  • Indications Intermediate uveitis; Panuveitis; Posterior uveitis
  • Focus Registrational; Therapeutic Use
  • Acronyms Visual I
  • Sponsors Abbott Healthcare; AbbVie

Most Recent Events

  • 01 Dec 2017 Results of a post-hoc analysis from VISUAL-1 and VISUAL-2 studies assessing the association between corticosteroid dosage and incidence rates of corticosteroid-related adverse events, published in the Ophthalmology.
  • 17 Jun 2017 Results of exploratory analysis of VISUAL I and VISUAL II trials presented at the 18th Annual Congress of the European League Against Rheumatism.
  • 28 Sep 2016 According to an AbbVie and Eisai media release, based on the results of VISUAL-I and VISUAL-II, and VISUAL-III , adalimumab was granted additional approval in Japan, for the treatment of non-infectious intermediate, posterior and panuveitis, regardless of underlying disease.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top